Close this search box.

Venture report: Mirador’s $400M launch; megarounds for Clasp, Capstan, Engrail

ARTICLE | Finance

Arch backs immunology/fibrosis start-up; JHU spinout launches with $150M; San Diego-based pair advance clinical plans in oncology and neuroscience

By Paul Bonanos, Director of Biopharma Intelligence

March 21, 2024 11:59 PM UTC

The year’s largest venture funding thus far went to newly launched Mirador, whose data-driven approach to finding new targets in inflammation and fibrosis drew interest from a large syndicate led by Arch. Meanwhile, nine-figure rounds went to a trio of other biotechs this week, including newly launched Clasp and San Diego-based start-ups Capstan and Engrail.

Mirador Therapeutics Inc. emerged from stealth Thursday with more than $400 million and a team led by former executives from Prometheus Biosciences Inc. The start-up believes it can use a database with millions of patients’ molecular profiles to discover targets associated with disease states and learn about interactions that could lead to combination therapies. Its platform, Mirador360, is also designed to develop diagnostics and stratify patients…